For weight management or cardiovascular risk reduction, the U.S. Wegovy label specifies at least two months before a planned pregnancy [1]. The U.S. Zepbound label gives no fixed interval before conception [2]. Bring the exact product and reason for taking it to a preconception visit.
What the U.S. labels say
For weight management or cardiovascular risk reduction, the Wegovy label also calls for stopping when pregnancy is recognized [1]. People taking Wegovy for MASH need a separate discussion about potential benefits and fetal risks. The label specifies the same two-month interval if potential risks outweigh benefits.
The Zepbound label addresses two decisions. Its warning about tirzepatide and birth control pills applies to preventing pregnancy. The label also calls for stopping Zepbound when pregnancy is recognized [2].
What pregnancy records can tell us
Our review of U.S. prescribing around pregnancy describes when prescriptions were recorded before and after delivery. Those records measure prescribing patterns. They cannot establish whether a medication is safe at a given point in pregnancy.
One health system matched 448 pregnancies with prior or early GLP-1 orders to 1,344 pregnancies without those orders [3]. The exposed group gained more weight during pregnancy, on average. The study design could not establish how much of the difference came from stopping the drug.
A multinational study included 938 infants with early GLP-1 prescription exposure among pregnancies in people with type 2 diabetes [4]. The adjusted risk ratio for major malformations versus insulin was 0.95 (95% CI 0.72 to 1.26). The estimate leaves uncertainty about risk. The study also grouped several GLP-1 drugs together.
What to bring to a preconception visit
Bring your medication name, the reason you use it, and the date of your last dose. Discuss a glucose management plan if you take the drug for diabetes. If pregnancy comes sooner than expected, contact the prescriber and obstetric team promptly about the specific drug and indication.